9999999997-17-008176.txt : 20170822 9999999997-17-008176.hdr.sgml : 20170822 20170822095815 ACCESSION NUMBER: 9999999997-17-008176 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170822 DATE AS OF CHANGE: 20170822 ACTION DATE: 20170822 RECEIVED DATE: 20170822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 171044277 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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